SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Seagen Inc. – ‘8-K’ for 8/12/22

On:  Friday, 8/12/22, at 3:06pm ET   ·   For:  8/12/22   ·   Accession #:  1193125-22-219784   ·   File #:  0-32405

Previous ‘8-K’:  ‘8-K’ on / for 7/28/22   ·   Latest ‘8-K’:  This Filing

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/12/22  Seagen Inc.                       8-K:8,9     8/12/22   11:151K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     23K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML      9K 
 6: R1          Document and Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- d379118d8k_htm                      XML     13K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- sgen-20220812_lab                     XML     53K 
 5: EX-101.PRE  XBRL Presentations -- sgen-20220812_pre              XML     34K 
 3: EX-101.SCH  XBRL Schema -- sgen-20220812                         XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
11: ZIP         XBRL Zipped Folder -- 0001193125-22-219784-xbrl      Zip     13K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
  8-K  
 i false  i 0001060736 0001060736 2022-08-12 2022-08-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM  i 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i August 12, 2022

 

 

 i Seagen Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

 i Delaware    i 0-32405    i 91-1874389

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S Employer

Identification No.)

 i 21823 30th Drive SE

 i Bothell,  i Washington  i 98021

(Address of principal executive offices, including zip code)

 i (425)  i 527-4000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

 i Common Stock, par value $0.001    i SGEN    i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 


Item 8.01

Other Events

On August 12, 2022, Seagen Inc. issued a press release regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. relating to the parties’ 2008 collaboration agreement for the use of Seagen’s antibody-drug conjugate technology. The press release is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

99.1    Press Release of Seagen Inc. dated August 12, 2022
104    Cover Page Interactive Data File (formatted in Inline XBRL)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SEAGEN INC.
Date: August 12, 2022     By:  

/s/ Jean I. Liu

      Jean I. Liu
      Chief Legal Officer

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:8/12/22None on these Dates
 List all Filings 
Top
Filing Submission 0001193125-22-219784   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Sep. 27, 7:41:27.1pm ET